This is a working overview of BDNF, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-10 and is reviewed periodically as new material appears.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
| Property | Value | Notes |
|---|---|---|
| Route studied | Intranasal | Predominant route in published reports |
| Circulation stability | Short, minutes scale | Peptidases cleave it; the tail slows the process |
| Analytical method | RP-HPLC with mass spectrometry | Used for identity and purity assessment |
| Reported outcome domains | Anxiety and cognitive measures | Derived from small, mostly regional trials |
| Regulatory status | Marketed in Russia | Availability outside that market is limited |
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
=== Sense and sensitivity === In clinical microbiology labs, the quantitation of microbial burden is considered a routine function as it is associated with the severity and progression of the disease. To achieve a good quantitation a high sensitivity of the technique is needed. Whereas interfering substances represent a common problem to clinical chemistry or to PCR diagnostics, the degree of interference from host (for example, in tissue biopsies) or nonpathogen nucleic acids (for example, in stool) in metagenomics is a new twist. In addition, due to the relative size of the human genome in comparison with microbial genomes the interference can occur at low levels of contaminating material. Another challenge for clinical metagenomics in regards to sensitivity is the diagnosis of coinfections where there are present high-titer pathogens that can generate biased results as they may disproportionately soak up reads and make difficult to distinguish the less predominant pathogens. In addition to issues with interfering substances, specially in the diagnosis area, accurate quantitation and sensitivities are essential as a confusion in the results can affect to a third person, the patient. For these reason, practitioners currently have to be keenly aware of the index-swapping issues associated with Illumina sequencing which can lead to trace incorrectly barcoded samples. Since metagenomics has typically been used on patients for whom every other test to date has been negative, questions surrounding analytical sensitivity haven been less germane.
GLP-1 has also shown signs of carrying out protective and regulatory effects in numerous other tissues, including heart, tongue, adipose, muscles, bones, kidneys, liver and lungs. GLP-1 receptor agonists e.g., semaglutide, liraglutide commonly cause gastrointestinal adverse effects such as nausea, vomiting, diarrhea, constipation, and abdominal discomfort, especially during dose escalation, less common risks include pancreatitis, gallbladder disease, and hypoglycemia mainly with insulin sulfonylureas.
Given the uniparental care observed in modern crocodilians and basal (early-diverging) birds, most non-avian dinosaurs including T. rex were likely uniparental as well. The authors also estimated that the relative size of tyrannosaurid hatchlings and eggs are larger than that of squamates, turtles, crocodilians, pterosaurs, and certain dinosaur clades (protoceratopsids and basal sauropodomorphs), but smaller than that of eumaniraptorans and modern birds, probably weighing less in both relative and absolute size than those of the elephant bird Aepyornis maximus and the South Island giant moa. Over half of the known T. rex specimens appear to have died within six years of reaching sexual maturity, a pattern which is also seen in other tyrannosaurs and in some large, long-lived birds and mammals today. These species are characterized by high infant mortality rates, followed by relatively low mortality among juveniles. Mortality increases again following sexual maturity, partly due to the stresses of reproduction. One study suggests that the rarity of juvenile T. rex fossils is due in part to low juvenile mortality rates; the animals were not dying in large numbers at these ages, and thus were not often fossilized. This rarity may also be due to the incompleteness of the fossil record or to the bias of fossil collectors towards larger, more spectacular specimens. In a 2013 lecture, Thomas Holtz Jr. suggested that dinosaurs "lived fast and died young" because they reproduced quickly whereas mammals have long lifespans because they take longer to reproduce. Gregory S.
Sources: en.wikipedia.org
The earliest known compilation of medicinal substances was the Sushruta Samhita, an Indian Ayurvedic treatise attributed to Sushruta in the 6th century BC. However, the earliest text as preserved dates to the 3rd or 4th century AD. Many Sumerian (4th millennium BC – early 2nd millennium BC) cuneiform clay tablets record prescriptions for medicine. Ancient Egyptian pharmacological knowledge was recorded in various papyri such as the Ebers Papyrus of 1550 BC, and the Edwin Smith Papyrus of the 16th century BC.
== Contraindications == Mohs surgery is generally contraindicated when the criteria summarized in the “Uses” section above are not met. For example, the tumor is small, low-risk, has well-defined margins, and is in a non-critical area. The standard protocol for Mohs surgery requires the surgeon to both remove the tissue and interpret the pathology. The procedure is not considered Mohs surgery if the removed tissue is sent and read by a pathologist instead of the surgeon performing the procedure. In this case, it is considered a standard excision and should be documented as such. Another doctor interpreting histopathology is incompatible with Mohs surgery. Relative contraindications include instances where the risks of surgery outweigh the benefits such as in patients with co-morbidities, in cases where the defect caused by surgery would need complex reconstruction beyond the scope of the surgery, or when patient factors such as severe bleeding predispositions or being unable to tolerate local anesthesia would affect the prognosis. Increased postoperative complications are associated with immunosuppressed patients (e.g. solid organ transplant recipients) and elderly patients. These are not absolute contraindications, but the risks of this procedure should be weighed against the benefits for each individual patient.
=== 1989 === January 7, 1989 – Japanese Emperor Hirohito dies, he was succeeded by his son Akihito. January 20, 1989 – George H. W. Bush becomes president of the United States. February 1989 – End of Soviet–Afghan War; continuation of internal conflict without Soviet troops. June 3, 1989 – Iranian leader Ayatollah Khomeini dies. June 4, 1989 – Tiananmen Square protests of 1989 in Beijing, People's Republic of China. June 4, 1989 – Solidarity's decisive victory in the first partially free parliamentary elections in post-war Poland sparks off a succession of anti-communist Revolutions of 1989 across Central, later South-East and Eastern Europe. August 14, 1989 – South African president Pieter Willem Botha resigns in reaction to the implementation of Tripartite Accord. August 19, 1989 – The opening of the border gate between Austria and Hungary at the Pan-European Picnic set in motion a chain reaction, at the end of which there was no longer a GDR and the Eastern Bloc had disintegrated. August 23, 1989 – Soviet Politburo member Alexander Yakovlev denounces the secret protocols of the Hitler-Stalin Pact. August 24, 1989 – Tadeusz Mazowiecki becomes the prime minister of Poland forming the first non-communist government in the Communist bloc. October 23, 1989 – End of Communism in Hungary. November 9, 1989 – Fall of the Berlin Wall. November 24, 1989 – Communist Party of Czechoslovakia leaders resign during the Velvet Revolution, effectively ending one-party rule in that country.
On February 6, U.S. Border Patrol chief Michael W. Banks claimed that illegal border crossings were already down almost 90% since Trump's inauguration, and that criminal prosecutions of those apprehended were up more than 50%. On February 25, Trump announced that the US would launch "Gold Card" residency permits for wealthy immigrants for a price of US$5 million, with an estimated release near the end of March 2025. Trump deported 37,660 people during his first month in office. In response to injunctions countering his deportations, Trump considered suspending habeas corpus. Stephen Miller in May 2025 said regarding immigration cases that "habeas corpus can be suspended in a time of invasion", and that the Trump administration was "actively looking at" carrying out such a suspension, depending on "whether the courts do the right thing or not"; Article One of the United States Constitution forbids such a suspension "unless when in cases of rebellion or invasion the public safety may require it". On July 1, Trump toured a newly built facility in the Florida Everglades nicknamed "Alligator Alcatraz". This facility is designed to keep 3,000 persons in detention. On July 10, the Department of Health and Human Services announced they would be restricting undocumented immigrants from enrolling for Head Start, a federally funded U.S. preschool program. The administration announced on August 21, 2025, that it would be reviewing all 55 million visa holders in the United States.
Sources: en.wikipedia.org
The pellagra epidemic in the American south had subsided in periods of low cotton production (late 1910s to early 1920s, the Great Depression), but it had consistently rebounded as cotton production recovered. The cause would not be understood until 1937, when the relation with niacin was discovered. Voluntary food fortification and periods of mandatory fortification on the state and federal levels soon followed, coinciding with a continuous drop in pellagra deaths. By the 1950s, the disease was virtually eliminated from the US.
=== Protein purification === Because of the mild elution conditions (biotin plus wash buffer) SBP-Tagged proteins can be generated in a relatively pure state with a single purification step. There are several relatively abundant mammalian proteins that inherently associate with the IMAC matrices that bind to the more commonly used Polyhistidine-tag (His-tag). For this reason non-IMAC purification protocols, including with the SBP-Tag, are often preferred for proteins that are expressed in mammalian cells.
A schematic diagram of instrumentation which can be used for electron ionization is shown to the right. The ion source block is made out of metal. As the electron source, the cathode, which can be a thin filament of tungsten or rhenium wire, is inserted through a slit to the source block. Then it is heated up to an incandescent temperature to emit electrons. A potential of 70 V is applied between the cathode and source block to accelerate them to 70 eV kinetic energy to produce positive ions. The potential of the anode (electron trap) is slightly positive and it is placed on the outside of the ionization chamber, directly opposite to the cathode. The unused electrons are collected by this electron trap. The sample is introduced through the sample hole. To increase the ionization process, a weak magnetic field is applied parallel to the direction of the electrons' travel. Because of this, electrons travel in a narrow helical path, which increases their path length. The positive ions that are generated are accelerated by the repeller electrode into the accelerating region through the slit in the source block. By applying a potential to the ion source and maintaining the exit slit at ground potential, ions enter the mass analyzer with a fixed kinetic energy. To avoid the condensation of the sample, the source block is heated to approximately 300 °C.
Sources: en.wikipedia.org
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.
Intranasal delivery is the route described in most published work. It is used because the peptide is degraded quickly once it reaches circulation. Direct evidence of brain penetration in humans is lacking.
Most trials are small, regionally concentrated, and often lack rigorous blinding or placebo control. Independent replication is limited. Reviews in English generally rate the evidence as preliminary.
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.